SUVEN LIFE SCIENCES LTD. - 530239 - Board Meeting Outcome for Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended December 31, 2022.
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company at its meeting held today i.e. February 02, 2023, has taken on record and approved Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended December 31, 2022. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for quarter ended December 31, 2022. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period are accessible to everyone at below mentioned web link: www.suven.com/Patentupdates.aspx02-02-2023